KAIGENE

What this means for you

Not registered yet, but its 30 Jun 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99259208

Mark type

Stylized text

Filed

30 Jun 2025

Attorney of record

Devon E. White

Goods and services

• Class 001 — Chemicals: Chemical preparations for scientific purposes; Molecules for use in industry, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for use in science, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for molecular biology, other than for medical or veterinary use, namely, protein-modulating molecules for use in the pharmaceutical industry
• Class 005 — Pharmaceuticals: Pharmaceutical and therapeutic preparations for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical preparations, namely, a drug formulation using protein degradation for use in treating immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical and therapeutic preparations for modulating protein degradation pathways; Biochemical preparations for medical use for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical preparations for targeted protein degradation, comprising small molecules, peptides, biologics, antibodies designed for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Proteins, protein fragments, and protein conjugates all for use in the manufacture of pharmaceutical preparations for treatment of immunologic diseases, particularly autoimmune diseases
• Class 042 — Scientific and technological services: Research and development in the pharmaceutical and biotechnology fields; Medical and pharmaceutical research services in relation to protein degradation; Providing medical and scientific research information in the field of biochemical, therapeutic, and pharmaceutical preparations; Research and development of platform technology, namely, a biological platform for manufacturing therapeutics for the treatment of autoimmune diseases; Research and development of platform technology, namely, a platform for research and development of pharmaceuticals for the treatment of autoimmune diseases; Development of platform technology, namely, biotherapeutic platforms for use in manufacturing pharmaceuticals and therapeutics; Medical and scientific research, namely, conducting clinical trials for others; Laboratory research services relating to pharmaceuticals; Scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; Scientific and technological consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; Providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; Custom development of pharmaceutical and biopharmaceutical products; Providing evaluation testing for pharmaceutical and biopharmaceutical products featuring protein degradation; Pre-clinical and non-clinical evaluation testing of pharmaceutical and biopharmaceutical products; Pharmaceutical and biopharmaceutical research and development featuring protein degradation for others; Pharmaceutical research for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Medical and pharmaceutical research in relation to targeted therapies that degrade disease driving membrane and extracellular proteins; Testing, inspection, research, or development of pharmaceutical preparations; Providing an on-line searchable database featuring protein molecules for scientific research purposes; Providing on-line non-downloadable software program for use in the discovery and development of targeted proteins used to develop treatments for diseases; Providing on-line non-downloadable software program for use in the discovery and development of targeted proteins used to develop medicines; Providing on-line non-downloadable software program for identifying, searching, and screening protein molecules; Providing on-line non-downloadable software program for searching within a library of protein molecules; Providing medical and scientific research information; Consulting services in the field of genetic science

Owner

• Kaigene, Inc., Rockville, MD, US

Prosecution history

• 13 Feb 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 13 Feb 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 19 Nov 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 19 Nov 2025 — NON-FINAL ACTION E-MAILED
• 19 Nov 2025 — NON-FINAL ACTION WRITTEN
• 18 Nov 2025 — ASSIGNED TO EXAMINER
• 04 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 30 Jun 2025 — APPLICATION FILING RECEIPT MAILED
• 30 Jun 2025 — NEW APPLICATION ENTERED